172 related articles for article (PubMed ID: 30754680)
1. In Silico Study Probes Potential Inhibitors of Human Dihydrofolate Reductase for Cancer Therapeutics.
Rana RM; Rampogu S; Zeb A; Son M; Park C; Lee G; Yoon S; Baek A; Parameswaran S; Park SJ; Lee KW
J Clin Med; 2019 Feb; 8(2):. PubMed ID: 30754680
[TBL] [Abstract][Full Text] [Related]
2. In Silico Study Identified Methotrexate Analog as Potential Inhibitor of Drug Resistant Human Dihydrofolate Reductase for Cancer Therapeutics.
Rana RM; Rampogu S; Abid NB; Zeb A; Parate S; Lee G; Yoon S; Kim Y; Kim D; Lee KW
Molecules; 2020 Jul; 25(15):. PubMed ID: 32752079
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore-based virtual screening and density functional theory approach to identifying novel butyrylcholinesterase inhibitors.
Sakkiah S; Lee KW
Acta Pharmacol Sin; 2012 Jul; 33(7):964-78. PubMed ID: 22684028
[TBL] [Abstract][Full Text] [Related]
4. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW
J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500
[TBL] [Abstract][Full Text] [Related]
5. Computational Simulations Identified Two Candidate Inhibitors of Cdk5/p25 to Abrogate Tau-associated Neurological Disorders.
Zeb A; Son M; Yoon S; Kim JH; Park SJ; Lee KW
Comput Struct Biotechnol J; 2019; 17():579-590. PubMed ID: 31073393
[TBL] [Abstract][Full Text] [Related]
6. In silico screening of inhibitors against human dihydrofolate reductase to identify potential anticancer compounds.
Soofi A; Rezaei-Tavirani M; Safari-Alighiarloo N
J Biomol Struct Dyn; 2023; 41(23):14497-14509. PubMed ID: 36883866
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modeling, molecular docking, and molecular dynamics simulation approaches for identifying new lead compounds for inhibiting aldose reductase 2.
Sakkiah S; Thangapandian S; Lee KW
J Mol Model; 2012 Jul; 18(7):3267-82. PubMed ID: 22249747
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophore modeling, virtual screening, molecular docking studies and density functional theory approaches to identify novel ketohexokinase (KHK) inhibitors.
Kavitha R; Karunagaran S; Chandrabose SS; Lee KW; Meganathan C
Biosystems; 2015 Dec; 138():39-52. PubMed ID: 26521124
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore modeling and virtual screening studies of checkpoint kinase 1 inhibitors.
Chen JJ; Liu TL; Yang LJ; Li LL; Wei YQ; Yang SY
Chem Pharm Bull (Tokyo); 2009 Jul; 57(7):704-9. PubMed ID: 19571415
[TBL] [Abstract][Full Text] [Related]
10. Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations.
Rampogu S; Baek A; Zeb A; Lee KW
BMC Cancer; 2018 Mar; 18(1):264. PubMed ID: 29514608
[TBL] [Abstract][Full Text] [Related]
11. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW
Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418
[TBL] [Abstract][Full Text] [Related]
12. Ligand-based pharmacophore modeling and Bayesian approaches to identify c-Src inhibitors.
Sakkiah S; Arullaperumal V; Hwang S; Lee KW
J Enzyme Inhib Med Chem; 2014 Feb; 29(1):69-80. PubMed ID: 23432516
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore modeling coupled with molecular dynamic simulation approach to identify new leads for meprin-β metalloprotease.
Chaudhuri A; Hudait N; Chakraborty SS
Comput Biol Chem; 2019 Jun; 80():292-306. PubMed ID: 31054542
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel NAMPT inhibitors based on pharmacophore modeling and virtual screening techniques.
Yi Q; Zhou L; Shao X; Wang T; Bao G; Shi H; Zhou S; Li X; Tian Y
Comb Chem High Throughput Screen; 2014; 17(10):868-78. PubMed ID: 25413783
[TBL] [Abstract][Full Text] [Related]
15. Novel chemical scaffolds of the tumor marker AKR1B10 inhibitors discovered by 3D QSAR pharmacophore modeling.
Kumar R; Son M; Bavi R; Lee Y; Park C; Arulalapperumal V; Cao GP; Kim HH; Suh JK; Kim YS; Kwon YJ; Lee KW
Acta Pharmacol Sin; 2015 Aug; 36(8):998-1012. PubMed ID: 26051108
[TBL] [Abstract][Full Text] [Related]
16. Pharmacophore mapping of a series of 2,4-diamino-5-deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase.
Debnath AK
J Med Chem; 2002 Jan; 45(1):41-53. PubMed ID: 11754578
[TBL] [Abstract][Full Text] [Related]
17. Ligand-based virtual screening and molecular docking studies to identify the critical chemical features of potent cathepsin D inhibitors.
Sakkiah S; Thangapandian S; Lee KW
Chem Biol Drug Des; 2012 Jul; 80(1):64-79. PubMed ID: 22269155
[TBL] [Abstract][Full Text] [Related]
18. In silico screening and study of novel ERK2 inhibitors using 3D QSAR, docking and molecular dynamics.
Larif S; Salem CB; Hmouda H; Bouraoui K
J Mol Graph Model; 2014 Sep; 53():1-12. PubMed ID: 25064438
[TBL] [Abstract][Full Text] [Related]
19. 3D QSAR pharmacophore-based virtual screening for the identification of potential inhibitors of tyrosinase.
Ghayas S; Ali Masood M; Parveen R; Aquib M; Farooq MA; Banerjee P; Sambhare S; Bavi R
J Biomol Struct Dyn; 2020 Jul; 38(10):2916-2927. PubMed ID: 31334690
[TBL] [Abstract][Full Text] [Related]
20. Discover potential inhibitors for PFKFB3 using 3D-QSAR, virtual screening, molecular docking and molecular dynamics simulation.
Bao Y; Zhou L; Dai D; Zhu X; Hu Y; Qiu Y
J Recept Signal Transduct Res; 2018; 38(5-6):413-431. PubMed ID: 30822195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
